2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA


Analysis from... | May 11, 2023

Related Keywords

Belgium ,University Of Texas ,Texas ,United States ,Chicago ,Illinois ,Germany ,Heidelberg ,Baden Wüberg ,Leuven ,Region Flamande ,France ,Houston ,Melissa Alsina ,Steve Bernstein ,Bristol Myers Squibb ,Michel Delforge ,Hemophagocytic Lymphohistiocytosis ,Julia Piasecki ,Yi Lin ,Krina Patel ,Salomon Manier ,Afshin Mashadi Hossein ,Marcs Raab ,Nasdaq ,European Hematology Association ,Md Anderson Cancer Center ,Heidelberg University Hospital ,Centre Hospitalier Universitaire De Lille ,University Of Leuven ,Linkedin ,Moffitt Cancer Center ,Twitter ,American Society Of Clinical Oncology ,American Society ,Clinical Oncology ,Annual Meeting ,Nicholas Stong ,Cancer Center ,Mayo Clinic ,Profit Share Agreement ,Release Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Igg Secondary Malignancies ,Operate Machinery ,Prescribing Information ,Cautionary Note Regarding Forward Looking ,2seventy Bio ,Nc Stock Exchange ,News ,Information ,Press Release ,Subgroup ,Analysis ,F ,Outcomes ,Or ,Patients ,Ith ,Relapsed ,End ,Refractory ,Multiple ,Myeloma ,Rom ,The ,Pivotal ,Hase , ,Trial ,Accepted ,Mural ,Presentation ,T Tsvt Us9013841070 ,